Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner


...see all

Biobanking industry will generate $22.7bn in 2018 predicts new study

A new report by Visiongain forecasts the worldwide medical biobanking industry will gain revenues of $22.7 billion in 2018. That industry will generate $14.4 billion in 2014, according to Biobanking for Medicine: Technology, Industry and Market 2014-2024, published in March 2014. Visiongain is a business information publisher in London, UK.


Visiongain predicts that world biobanking industry will expand fast in the first half of the forecast period 2014 to 2024. That sales expansion will be driven by rising demand for biobanked samples for use by pharmaceutical companies in preclinical research. Also increasing harmonisation and networking among medical biobanks means more high quality human biological samples (HBS) exist for use in research studies, also promoting biobanking revenue growth.


Jennifer Taylor, a pharmaceutical industry analyst in Visiongain, said: “The biobanking industry lies in a high growth phase. Nearly two thirds of the world’s biobanks have been established in the past decade and, with the increasing establishment of biobank networks and infrastructure, access to and use of banked HBS increases. Biobanking changes approaches to drug target identification, drug discovery and development, and is vital in efforts towards personalised medicine. It’s also clear that human biological samples in biobanks are valuable, and more and more people recognise this. However, despite efforts to condense that industry, its market remains fragmented at present, in early 2014.


“The biobanking industry is vast and developing. Our definition also encompasses the stem cell banking market for future therapeutic use. That is a rapidly growing sector, driven by rising public awareness of the potential of stem cell treatments. Also, with the recent offering of adult stem cell banking services in addition to umbilical cord blood banking, there exists a wide user base for that industry’s products and services. The stem cell banking industry for therapeutic use experiences rapid growth, then – although it faces challenges, particularly in countries where such activities are restricted.”


Visiongain’s new investigation shows revenue forecasts to 2024 at world market, submarket and national level. It forecasts biobanking for research and for therapeutic uses in human medicine.


That study gives individual revenue predictions to 2024 for nine submarkets at world level:


Biobanking for research
Biobanking for therapeutic uses.


It also forecasts the number of samples stored in those two fields. And it gives biobanking revenue forecasting to 2024 by research application:


Human tissues (also with sub-forecasts for public sector and commercial uses)
Stem cells
Other biological sample banking applications (inc. DNA and body fluids).


And that work predicts stem cell banking revenues to 2024 for therapeutic uses:


Umbilical cord stem cell banking
Adult stem cell banking.


It also forecasts the number of stem cell samples banked.


Furthermore that report analyses 12 leading national markets for biobanking, providing revenue forecasts to 2024 for each:


United States (US)
Germany, France, UK, Italy, Spain (EU5) and Netherlands
Brazil, Russia, India and China (BRIC nations).


It examines and compares leading companies in that industry. That work also discusses systems, software, consumables and services used by biobanks. The analysis gives 72 tables, 73 charts, and five interviews with authorities in that industry.


Biobanking for Medicine: Technology, Industry and Market 2014-2024 adds to Visiongain’s range of analytical reports on industries and markets in healthcare.


For further information about Visiongain’s report Biobanking for Medicine: Technology, Industry and Market 2014-2024 please visit http://www.visiongain.com/Report/1229/Biobanking-for-Medicine-Technology-Industry-and-Market-2014-2024

Contact:Sara Peerun on sara.peerun@visiongainglobal.com Tel: +44 (0) 20 7336 6100

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100


About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 


read more

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.